Figure 1.

A schematic workflow of clinical trial recruitment in secondary prevention trials. This figure shows a schematic workflow of clinical trial recruitment in secondary prevention trials of Alzheimer’s disease. It demonstrates how both pre-screening and screening phases of trial recruitment can benefit from clinical prediction models. It also shows how the priority of pre-screening is to have a low cost model, while the priority of screening is to have high accuracy biomarkers which can truly detect individuals who have abnormal Alzheimer’s disease pathology.